Table 2.
Adjusted p-values (Tukey’s post hoc) for all significantly different means of the difference between eyes for refractive error (dRE) and axial lengths (dAL) from atropine-, NOS inhibitor-, and D-NMMA-treatment experiments.
| Treatment Groups | dRE | dAL |
|---|---|---|
| PBS vs. Atropine (Atro) | <0.0001 | 0.0006 |
| PBS vs. D-NMMA | 0.0331 | |
| PBS vs. Atro + D-NMMA | <0.0001 | 0.0012 |
| Atro vs. D-NMMA | <0.0001 | |
| Atro vs. L-NMMA | <0.0001 | |
| Atro vs. Atro + L-NMMA | <0.0001 | 0.0321 |
| Atro vs. L-NIO | <0.0001 | |
| Atro vs. Atro + L-NIO | <0.0001 | 0.0019 |
| D-NMMA vs. Atro + D-NMMA | <0.0001 | |
| Atro + D-NMMA vs. L-NMMA | <0.0001 | 0.0173 |
| Atro + D-NMMA vs. Atro + L-NMMA | <0.0001 | |
| Atro + D-NMMA vs. L-NIO | <0.0001 | 0.0281 |
| Atro + D-NMMA vs. Atro + L-NIO | <0.0001 | 0.0013 |
*dRE: difference refractive errors; dAL: difference axial lengths.